# Netupitant + Palonosetron

## Akynzeo 300/0.5mg

| TAH Drug Code      | [OAKY](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OAKY)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Prevention of acute and delayed nausea and vomiting caused by initial and recurrent cancer chemotherapy (not limited to highly emetogenic chemotherapy).                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Dosing             | Highly emetogenic chemotherapy (including cisplatin-based regimens): Administer netupitant 300 mg/palonosetron 0.5 mg (1 capsule) orally 1 hour prior to chemotherapy on day 1; coadminister dexamethasone 12 mg orally 30 minutes prior to chemotherapy on day 1， and 8 mg QD through day 2 to day 4. Anthracycline and cyclophosphamide-based regimens and other regimens not highly emetogenic: Administer netupitant 300 mg/palonosetron 0.5 mg (1 capsule) orally 1 hour prior to chemotherapy on day 1; coadminister dexamethasone 12 mg orally 30 minutes before chemotherapy on day 1. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Specific contraindications have not been determined.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Adverse Effects    | Common Dermatologic: Erythema (3% ) Gastrointestinal: Constipation (3% )， Indigestion (4% ) Musculoskeletal: Asthenia (8% ) Neurologic: Headache (9% ) Other: Fatigue (4% to 7% ) Serious Other: Serotonin syndrome                                                                                                                                                                                                                                                                                                                                                                            |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| More Info          | [UpToDate](https://www.uptodate.com/contents/netupitant-and-palonosetron-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

